GCCL Completes Proactive Development of Biosimilar Clinical Trial Analysis Methods, Providing Customized Analysis Services through Enhanced R&D Capabilities
PR NewswireJul 17, 2024
Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockbuster drugs such as 'Keytruda' and 'Yervoy', GCCL offers tailored clinical trial analysis services for biosimilar development YONGIN, South Korea, July 17, 2024 /PRNewswire/ -- GCCL, a clinical trial sample analysis institution, has proactively developed pharmacokinetic (PK) analysis methods for blockbuster drugs' biosimilars and off